- Home
- AZTR vs NUWE Comparison
AZTR vs NUWE Comparison
Compare AZTR & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTR
- NUWE
- Stock Information
- Founded
- AZTR 2014
- NUWE 1999
- Country
- AZTR United States
- NUWE United States
- Employees
- AZTR 12
- NUWE N/A
- Industry
- AZTR Biotechnology: Pharmaceutical Preparations
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AZTR Health Care
- NUWE Health Care
- Exchange
- AZTR Nasdaq
- NUWE Nasdaq
- Market Cap
- AZTR 4.0M
- NUWE 3.9M
- IPO Year
- AZTR 2023
- NUWE N/A
- Fundamental
- Price
- AZTR $0.26
- NUWE $0.23
- Analyst Decision
- AZTR
- NUWE Strong Buy
- Analyst Count
- AZTR 0
- NUWE 1
- Target Price
- AZTR N/A
- NUWE $17.00
- AVG Volume (30 Days)
- AZTR 4.6M
- NUWE 30.9M
- Earning Date
- AZTR 08-11-2025
- NUWE 08-12-2025
- Dividend Yield
- AZTR N/A
- NUWE N/A
- EPS Growth
- AZTR N/A
- NUWE N/A
- EPS
- AZTR N/A
- NUWE N/A
- Revenue
- AZTR $7,500.00
- NUWE $8,787,000.00
- Revenue This Year
- AZTR N/A
- NUWE $6.53
- Revenue Next Year
- AZTR N/A
- NUWE $51.63
- P/E Ratio
- AZTR N/A
- NUWE N/A
- Revenue Growth
- AZTR N/A
- NUWE N/A
- 52 Week Low
- AZTR $0.23
- NUWE $0.21
- 52 Week High
- AZTR $12.00
- NUWE $6.61
- Technical
- Relative Strength Index (RSI)
- AZTR 46.07
- NUWE 26.12
- Support Level
- AZTR $0.23
- NUWE $0.21
- Resistance Level
- AZTR $0.36
- NUWE $0.32
- Average True Range (ATR)
- AZTR 0.02
- NUWE 0.07
- MACD
- AZTR -0.00
- NUWE 0.00
- Stochastic Oscillator
- AZTR 26.79
- NUWE 11.43
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.